Tuesday, June 29, 2021

Fw: Ref.: (LML) Web documentary on the Principles and Guidelines for the elimination of discrimination against persons affected by leprosy - watch now!

 

 


Leprosy Mailing List – June 29,  2021

 

Ref.:  (LML) Web documentary on the Principles and Guidelines for the elimination of discrimination against persons affected by leprosy - watch now!

 

From:  Nanda Duarte, Rio de Janeiro, Brazil

 

 

 

Dear Pieter and colleagues,

 

Check out the premiere on the Special Rapporteur Alice Cruz's channel: the web documentary "Principles and Guidelines for the elimination of discrimination against persons affected by leprosy and their family members - From the draft to law in action".

 https://bit.ly/FromTheDraftToLawInAction

The audio-visual project tells a bit of the story behind the elaboration of the Draft set of principles and guidelines for the elimination of discrimination against persons affected by leprosy and their family members, that accompany the resolution 65/215, which was unanimously approved by the United Nations General Assembly in December 2010.

This web documentary explains what this document means in the context of international human rights, tells the story of how this human rights instrument came to exist and how it was drafted, but also how it connects to the lived experience of the people it protects, bringing together testimonies from persons affected by leprosy and their family members from different parts of the world, who talk about the challenges they faced and still face in order to have their human rights respected.  

Participations (in order of appearance):  Alice Cruz (UN Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members);  Yohei Sasakawa (Japanese Goodwill Ambassador for the Human Rights of Persons Affected by Leprosy and WHO Goodwill Ambassador for Leprosy Elimination); Shigeki Sakamoto (former member of the UN Human Rights Council Advisory Committee); Ignacio Bastidas Vásquez and Salome (Felehansen - Colombia); Mangala Dhondge (The Leprosy Mission Trust India); Edimilson Picanço (Morhan - Brazil); and Maksuda Begum (Lepra Bangladesh)

The Special Rapporteur Alice Cruz warmly thanks all the people who have generously contributed to this webdocumentary.

 

This webdocumentary aims at contributing to overall human rights education, please share it widely! 

 

 

Nanda Duarte, Morhan, Brazil

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to a topic in the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this topic, visit https://groups.google.com/d/topic/leprosymailinglist/B4_tpewQPAI/unsubscribe.
To unsubscribe from this group and all its topics, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/8462ecad-848b-4108-b474-6954a5aacf32n%40googlegroups.com.

Monday, June 28, 2021

Fw: Ref.: (LML) SR Leprosy/Hansen's disease Newsletter


 

 
Leprosy Mailing List – June 28,  2021

 

Ref.:  (LML) SR Leprosy/Hansen's disease Newsletter

 

From:  Alice Cruz, Quinto, Ecuador

 

 

Dear friends and partners,

 

My team and I are very happy to share with you the first edition of my mandate's newsletter.


By attached file the first edition of the biannual newsletter of the  United Nations Mandate of the Special  Rapporteur on the Elimination of Discrimination Against Persons  Affected by Leprosy and their Family Members.  With this newsletter I, Alice Cruz,  aim  at  sharing information about my public activities as Special Rapporteur since the transition period from my first term to my second term (October/November 2020) until the end of the first  semester of 2021 (more exactly mid-June of 2021). This newsletter is a part of a continuous effort undertaken by my team and I, as well as many other stakeholders in the field, to enable  access to human rights related information to persons affected by leprosy and their family members. I encourage you to share this newsletter–and future ones- with people and organizations who might have an interest in this topic.


But first, a word on terminology:  a discussion among persons with the personal experience of leprosy and their representative organizations about  terminology regarding the disease and the people who experience it is ongoing, with some segments of the community preferring the terms "Hansen's disease" and "persons who have experienced Hansen's disease". I deeply  appreciate such a discussion, but as Special Rapporteur it is not up  to me to favor a particular term. Any change in terminology needs to result  from a collective agreement between  people with the personal experience of leprosy/Hansen ́s disease and their representative organizations. While I look forward to receive further guidance from them on  this matter, I will employ in  this first newsletter the terminology used by the Human Rights Council in its resolution 44/6.


Happy reading!

 

Alice

 

PORTUGUÊS

Queridxs amigxs e parceirxs.

A minha equipa e eu estamos muito felizes de partilhar com vocês a primeira edição do boletim de notícias do meu mandato.

Desejo a todxs uma boa leitura!

Alice

 

ESPAÑOL

Estimados amigxs y compañerxs,

Mi equipo y yo estamos muy contentos de compartir con ustedes la primera edición del boletín de mi mandato.

¡Les deseo a todxs una feliz lectura!

Alice

 

FRANÇAIS

Chers amis et partenaires,

Mon équipe et moi sommes très heureux de partager avec vous la première édition du bulletin de mon mandat. Souhaite à tous une bonne lecture!

Alice

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to a topic in the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this topic, visit https://groups.google.com/d/topic/leprosymailinglist/CPBRnMMFQlg/unsubscribe.
To unsubscribe from this group and all its topics, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/c862e301-383b-4e14-84f4-6d305a537152n%40googlegroups.com.

Sunday, June 27, 2021

Fw: Ref.: (LML) Super-spreaders and polar LL HD


Leprosy Mailing List – June 27,  2021

 

Ref.:  (LML) Super-spreaders and polar LL HD

 

From:  Joel Almeida, London and Mumbai

 

Dear Pieter and colleagues,

 

You might be interested in these articles that highlight why super-spreaders require attention if we are to beat infectious diseases.

 

https://www.ijidonline.com/article/S1201-9712(11)00024-5/fulltext

 

https://www.nature.com/articles/d41586-021-00460-x

 

(CC.BY 4.0 licence)

 

Detailed studies have been done in viral diseases transmitted by droplet infection/aerosol, quantifying over-dispersion (where a large proportion of infected people infect no others, or only a few others, whereas a small minority infect many.) (1) This is quantified in the "k value". The smaller the k value, the smaller the proportion of infected persons who infect several others. The k value is fairly small in COVID, which is another way of saying that super-spreaders are responsible for a significant proportion of new cases.

 

The k value is several orders of magnitude smaller in HD (leprosy), possibly the smallest of any disease. How so? Polar LL (lepromatous) patients unprotected against HD bacilli can shed as many as tens of millions of viable bacilli per day. This is in marked contrast to even BL (borderline lepromatous) patients (2) It would take tens of millions of unprotected BL patients, to equal a single unprotected polar LL patient in terms of viable bacilli shed per day (unless the BL patients remain untreated and downgrade to LL HD). And probably billions of PB (paucibacillary) HD patients. The importance of LL HD in transmission is accentuated by the good natural immunity in most people. This means that heroic doses of concentrated viable bacilli are required to infect a typical human who is not in the grip of extreme poverty. Unprotected polar LL patients can provide astronomical numbers of concentrated viable bacilli, making them overwhelmingly important in transmission.

 

 

Polar LL patients also are exceptionally prone to excruciatingly painful ENL episodes if MDT is withdrawn after 12 months. If polar LL patients do not receive special attention, not only do they suffer but also transmission continues. Transmission has devastating consequences for too many people in endemic areas. 

 

The incubation period of signs of reinfection is typically 6 years or more after withdrawal of anti-microbial protection, (3) and LLp patients are the most susceptible of all patients to (re)infection. Claims of low recurrence rates after 12 or 24 months of MDT in LL patients tend to be clouded by a few errors. The most common error is to include years zero to five after MDT in the denominator, and to mix LLp patients with others in the analysis. Also, to disregard changes in BI (bacillary index) at a single site, and to rely on inexpert (albeit trained) observers for diagnosis of recurrence. Such errors lead to underestimates of the critical risk, that of LLp patients being reinfected in endemic areas. 

 

For those not from a biological or statistical background, such errors are akin to underestimating the incidence rate of dysmenorrhea by including pre-pubertal girls, or any males, in the denominator. Dysmenorrhea, of course, is not transmitted nor does it lead to irreversible damage. How much more important it is, then, to avoid errors when estimating the risk of reinfection among LLp patients in endemic areas. 

 

Neglecting super-spreaders because they are a minority of patients would be an epidemiologically disastrous approach. To the HD bacilli, the human population and any susceptible hosts are nothing more than a culture plate. The priority is not to withhold anti-microbials from this culture plate, the human population, but to extinguish the infection before it blights more lives and before it develops resistance to affordable drugs.

 

Anti-microbial neglect of polar LL patients after 12 months of MDT is the central reason why 200,000 new cases have been detected every year (pre COVID), why huge areas remain entrapped in HD transmission, why LL patients suffer the excruciating pain of ENL, and why even otherwise well-run programmes fail to match the dramatic successes oKarigiri and Shandong. Those latter programmes relied on prolonged anti-microbial protection of LL patients, greatly reducing (re)infections and transmission. Their achievements hold important lessons.

 

As a community of science, compassion and justice, we aspire to end transmission and prevent ENL. To succeed, it is necessary to end the widespread anti-microbial neglect of polar LL patients who have completed 12 months of MDT. The evidence has been presented here at some length previously and can be rehearsed again at some length, in due course. 

 

Fortunately, LML has hundreds of experts capable of reviewing claims and refuting errors fairly rapidly. Errors can survive a handful of reviewers, or even committees, as frequently happens. However, the half-life of errors tends to be shorter on LML than almost anywhere else, because it is an open platform enabling rapid open publication, with a membership that includes nearly all the world's most knowledgeable experts. Esteemed colleagues here typically are keen to assist others so that we all can keep improving our understanding of why some control programmes succeed but too many fail even if they are well-run. 

 

We have the power to stop the infectiousness of genomically anergic super-spreaders (polar LL patients) in HD endemic areas, simply by adding sufficient anti-microbial protection against re-infection. We could champion quality care, not anti-microbial neglect. Prolonged anti-microbial protection of LL HD patients is a central pillar of quality care for them. It helps the patients avoid reinfection and evade the excruciating pain of ENL, as well as shutting down a major source of concentrated viable bacilli. It has transformed outcomes and impact in some formerly high endemic areas, and can do so in every endemic area. 

 

Wouldn't it be good to match the achievements of highly successful programmes by interrupting transmission? We can facilitate this in endemic areas simply by preventing re-infection among any patients likely to have LL HD. Prompt diagnosis and prolonged anti-microbial protection of genomically anergic polar LL HD patients are probably the most important and indispensable actions we can take to interrupt transmission in endemic areas. Otherwise anti-microbial neglect before and after MDT reduces them to unwitting and unwilling super-spreaders. 

 

Joel Almeida

 

References

 

1.     Endo A, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group, Abbott S et al. Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China [version 3; peer review: 2 approved]. Wellcome Open Res 2020, 5:67 (https://doi.org/10.12688/wellcomeopenres.15842.3

 

2.      Davey TF, Rees RJ. The nasal dicharge in leprosy: clinical and bacteriological aspects. Lepr Rev. 1974 Jun;45(2):121-34.

 

3.      Balagon MF, Cellona RV, dela Cruz E et al.  Long-Term Relapse Risk of Multibacillary Leprosy after Completion of 2 Years of Multiple Drug Therapy (WHO-MDT) in Cebu, Philippines. American Journal of Tropical Medicine and Hygiene, 2009; 81, 5: 895-9.  analysed in LML 2 June 2019

 

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 

--
You received this message because you are subscribed to a topic in the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this topic, visit https://groups.google.com/d/topic/leprosymailinglist/4qenBzjwplE/unsubscribe.
To unsubscribe from this group and all its topics, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/ef177654-bbc3-4244-a7dc-daed2bba0e67n%40googlegroups.com.

Fw: Ref.: (LML) Length of MDT

 

 


Leprosy Mailing List – June 27,  2021 

 

Ref.:  (LML) Length of MDT 

 

From:  Joel Almeida, London and Mumbai 


  

 

Dear Pieter and colleagues, 

 

Thanks to Prof. Lockwood for her contribution (LML 24 June 2021, Length of MDT). 

 

However, those views are not entirely available on the facts. In particular, the implication that 20 years of follow-up was available for all patients in a study is incorrect. Patients with as little as one year of follow-up were included in the denominator. This dilutes recurrence/reinfection rates. That is because the typical incubation period of signs of recurrence in LL patients is known to be higher in later years (typically later than five years) than in the first years following the withdrawal of MDT after 12 to 24 months. Diluted estimates and realistic estimates are two different things. 

 

A reasonable solution is to count how many persons were available for follow-up in each year following the withdrawal of MDT. That gives the year-specific denominator of recurrences/reinfections. For example, how many persons were available for follow-up in year 10, and how many of them were first detected to have signs of recurrence in year 10? That gives a reasonably informed estimate of the year-specific recurrence/reinfection rate in year 10 of follow-up. An example of such an analysis is available. The incubation period of signs of recurrence appears to be 6 years or more. The number of patients available for follow-up falls steadily, and very few patients tend to remain available for follow-up in years 15 to 20. For such reasons, estimates of recurrence/reinfection rates tend to be seriously diluted by the inclusion of the first five years of follow-up after the withdrawal of 12 to 24 months of MDT. 

 

More importantly, the ratio of the number of reinfected polar LL patients to newly diagnosed LL patients matters as much as the absolute value of recurrence/reinfection rates. If prevalent neglected polar LL patients with recurrence/reinfection outnumber incident (newly diagnosed) LL patients, then recurrence rates are too high. That is because transmission is maintained largely by accumulated recurrences/reinfections.  What is the incidence rate of LL HD (leprosy)? Usually well below 100 in a million, conspicuously less than in TB (tuberculosis). What is the long-term accumulated number of prevalent recurrences among polar LL patients? In the endemic population where I studied reinfections/recurrences in some detail (Karigiri, India), there were over 200 accumulated patients with recurrent high BI (after earlier smear negativity) in a population of about 450,000 persons. That equates to 444 per million accumulated prevalence of patients with recurrence showing high BI. With only 100 per million newly diagnosed LL HD patients and over 400 per million accumulated prevalence of high BI patients showing recurrence/reinfection, transmission is maintained to an important extent by previously treated LL patients. 

 

Transmission happens in otherwise well-run programmes largely because we have been enforcing anti-microbial neglect of anergic patients after 12 months of MDT. Incidentally, the much higher incidence rate of TB makes recurrences relatively less important drivers of transmission in TB than in HD. Therefore analogies between recurrence rates in TB and HD have limited value. The "acceptable" or epidemiologically inconsequential recurrence rate in HD is a fraction of that in TB because the incidence rate of HD is a fraction of that in TB. 

 

Importantly, denial of prolonged anti-microbial protection to high BI patients leads to avoidable ENL (erythema nodosum leprosum) episodes. These can be excruciatingly painful, driving patients to the brink of suicide. 

 

These are the reasons for ensuring prolonged-anti-microbial protection for every high BI patient, preferably after trying immunoprophylaxis with Mycobacterium w (MIP vaccine) in case a particular patient has phenotypic (sub-polar LL) rather than genomic anergy (polar LL). 

 

Further, claims of low recurrence rates among high BI patients tend to be undermined by mixing low (or even zero) BI patients with high BI patients in the analysis. This again dilutes recurrence/reinfection rates. Realistic estimates are quite different from diluted estimates.  

 

Missed or delayed diagnosis of recurrence/reinfection is another source of diluted recurrence/reinfection rates. This happens when an increase in BI at a single site is disregarded. Also when expert clinicians are not available for diagnosing recurrence/reinfection promptly.  

 

Polar LL patients in relatively less endemic areas are predicted and observed to be at lower risk of recurrence than those in more endemic areas. Therefore generalising from low endemic areas to high endemic areas tends to be misleading when it comes to reinfection/recurrence rates among high BI patients. 

 

The trouble with diluted estimates is that bacilli disregard them. 

 

Our choice is not difficult. We could follow the good example of enlightened colleagues in endemic areas who ensure prolonged anti-microbial protection for suspected polar LL patients. These colleagues are confronted by an accumulation of previously treated patients who show subtle signs of recurrence/reinfection. Skin smear microscopy shows acid fast bacilli. If skin smears are omitted or delayed, subtle signs are overlooked and anti-microbial protection is withheld, then neglected patients deteriorate to present with nodules, frank induration, and even ulceration accompanying very painful ENL. By contrast, prolonged anti-microbial protection reduces recurrence/reinfection as well as ENL and transmission.

There are options for prolonged anti-microbial protection of high BI patients in endemic areas. For destitute polar LL patients who rely on free-of-charge treatment, MDT continued beyond 12 months can suffice. For patients who can afford to pay, immunoprophylaxis with MIP can be followed by post-MDT chemoprophylaxis with a combination of bactericidal drugs.  

 

The alternative would be anti-microbial neglect of polar LL patients. The consequences would be severe, for the patients (including excruciatingly painful ENL) as well as the population of endemic areas (by continued transmission). Some countries experience persistently high transmission rates largely because they withhold prolonged anti-microbial protection from polar LL patients. This undermines their otherwise excellent programmes. It seems wiser to protect polar LL patients against reinfection in endemic areas, and so reduce transmission. This was the secret of success in Karigiri and Shandong. It can open the door to success in every endemic area. 

 

Joel Almeida 

 


LML - S Deepak, B Naafs, S Noto and P Schreuder 

LML blog link: http://leprosymailinglist.blogspot.it/ 

Contact: Dr Pieter Schreuder << editorlml@gmail.com  



Virus-free. www.avast.com

Ref.: (LML) InfoNTD monthly overview of the latest cross-cutting NTD publications - June, 2021

 


Leprosy Mailing List – June 27,  2021 

 

Ref.:  (LML) InfoNTD monthly overview of the latest cross-cutting NTD publications - June, 2021 

From:  Roos Geutjes. Amsterdam, the Netherlands 


  

 

Dear colleagues, 

Have you already looked at the WHO Skin NTDs online course collection with courses on podoconiosis, tungiasis and scabies? The WHO has confirmed that more courses on NTDs are being developed. Additionally, the COVID-19/NTD course is translated into French and Spanish and translations into Portuguese and Arabic are coming soon. This is fantastic news!  

At the bottom of this review, you will find  more information on upcoming events such as the NTD NGO Network annual conference (7 - 9 Sep), an interesting webinar on reaching the criteria to stop treatment for Onchocerciasis (24th Jun) and more. 

Enjoy reading the selection of the latest NTD publications that are listed below. Feel free to contact us to receive the full-text versions when a link to the full text is not included. We will also gladly support you with literature searches. Don't forget to scroll down to find more news and upcoming webinars! 


Warm regards,
Roos Geutjes

InfoNTD Coordinator
www.InfoNTD.org
info@InfoNTD.org  

 

 

Practical materials 

 

 

Podoconiosis: Training of health workers at national and district levels on skin-NTDs (online course)
World Health Organization. 2021.
Learn more
   


CBM's Community Mental Health Good Practice Guides
CBM. 2021.
Learn more
   

 

 

NTDs & COVID-19 

 

 

An assessment of the reported impact of the COVID-19 pandemic on leprosy services using an online survey of practitioners in leprosy referral centres
de Barros B, Lambert SM, Negera E, et al. Oxford University Press (OUP). Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021.
Read more 
   


COVID-19 and its impacts: The situation in Niger republic.
Nzeribe E, Michael U, Musa S, et al. Clinical epidemiology and global health. 2021.
Read more
   


Prospects for employment of persons with disabilities in the post-covid-19 era in developing countries
Morris F. Informa UK Limited. Disability & Society. 2021.
Read more
   

 

 

Other new publications 

 

 

The words we choose matter: recognising the importance of language in decolonising global health
Hommes F, Monzó HB, Ferrand RA, et al. Elsevier BV. The Lancet Global Health. 2021; 9 (7) : e897-e898. 
Read more
   


Report of the 23rd meeting of the WHO Alliance for the Global Elimination of Trachoma by 2020, 30 November–1 December 2020
World Health Organization . World Health Organization. 2021.
Read more
   


Increasing efficiencies from integrating control and elimination programmes for soil-transmitted helminths and schistosomiasis
Rollinson D, Sankar G, Stephens M, et al. Oxford University Press (OUP). International Health. 2021.
Read more
   


Improving Buruli ulcer control: steps towards decentralized care
Wadagni A. University of Groningen Press. 2021.
Read more
   


Model building and assessment of the impact of covariates for disease prevalence mapping in low-resource settings: to explain and to predict
Giorgi E, Fronterrè C, Macharia PM, et al. The Royal Society. Journal of The Royal Society Interface. 2021; 18 (179) : 20210104. 
Read more
   


Applied systems thinking: a viable approach to identify leverage points for accelerating progress towards ending neglected tropical diseases.
Glenn J, Kamara K, Umar Z, et al. Health research policy and systems. 2020; 18 (1) : 56.
Read more
   


Psychosocial burden of neglected tropical diseases in eastern Colombia: an explorative qualitative study in persons affected by leprosy, cutaneous leishmaniasis and Chagas disease
van Wijk R, van Selm L, Barbosa MC, et al. Cambridge University Press (CUP). Global Mental Health. 2021.
Read more
   


Primary health care facilities capacity gaps regarding diagnosis, treatment and knowledge of schistosomiasis among healthcare workers in North-western Tanzania: a call to strengthen the horizontal system
Mazigo HD, Uisso C, Kazyoba P, et al. Springer Science and Business Media LLC. BMC Health Services Research. 2021.
Read more
   


Bridging the gap: aligning economic research with disease burden.
Do L, Synnott P, Ma S, et al. BMJ global health. 2021.
Read more
   


How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
Vinkeles Melchers NVS, Stolk WA, Murdoch ME, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009489.
Read more
   


Onchocerciasis: diagnostic target product profile to support preventive chemotherapy
World Healh Organization . World Health Organization. 2021.
Read more
   


Morbidity Management and Disability Prevention of Lymphatic Filariasis
Sangamithra A, Dhavamani P. Shanlax International Journals. Shanlax International Journal of Economics. 2021; 9 (3) : 24-28. 
Read more
   


How can we achieve impact from public health research? A meta-ethnography of case studies
Gentry SV, Milden L, Kelly MP. Oxford University Press (OUP). Journal of Public Health. 2019; 43 (2) : 370-377.
Read more
   


A call for reforms in global health publications
Sharma D. Elsevier BV. The Lancet Global Health. 2021; 9 (7) : e901-e902. 
Read more
   


More than Stigma: Improving Wellbeing for People in Developing Countries
Anjadini SF. Linnaeus University. Design. 2021.
Read more
   


Global health in low-income and middle-income countries: a framework for action
Olufadewa I, Adesina M, Ayorinde T. Elsevier BV. The Lancet Global Health. 2021; 9 (7) : e899-e900. 
Read more
   


A strong effect of individual compliance with mass drug administration for lymphatic filariasis on sustained clearance of soil-transmitted helminth infections
Campillo JT, Awaca-Uvon NP, Tambwe J, et al. Springer Science and Business Media LLC. Parasites & Vectors. 2021.
Read more
   


Successes, challenges, and support for men versus women implementers in water, sanitation, and hygiene programs: A qualitative study in rural Nepal
Anderson DM, Gupta AK, Birken S, et al. Elsevier BV. International Journal of Hygiene and Environmental Health. 2021.
Read more
   


Caregiver burden in Buruli ulcer disease: Evidence from Ghana
Amoako YA, Ackam N, Omuojine J, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009454. 
Read more
   


Effectiveness of behaviour change techniques used in hand hygiene interventions targeting older children – A systematic review
Watson J, Cumming O, MacDougall A, et al. Elsevier BV. Social Science & Medicine. 2021.
Read more
   


Alternative approaches to lymphoedema care in lymphatic filariasis
Krishnasastry S, Mackenzie CD, Specht S. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (4) : e0009293.
Read more
   


Noma, a neglected disease: A viewpoint article
Farley E, Ariti C, Amirtharajah M, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009437. 
Read more
   


Eliminating onchocerciasis within the Meme River Basin of Cameroon: A social-ecological approach to understanding everyday realities and health systems
Nji TM, Piotrowski H, Dum-Buo N, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009433.
Read more
   


Quality of life in patients with Chagas disease and the instrument used: an integrative review
Baldoni NR, Quintino ND, Alves GCS, et al. FapUNIFESP (SciELO). Revista do Instituto de Medicina Tropical de São Paulo. 2021.
Read more
   


Implications of global environmental change for the burden of snakebite
Martín G, Yáñez-Arenas C, Rangel-Camacho R, et al. Elsevier BV. Toxicon: X. 2021.
Read  more
   


Effect of Lymphatic Filariasis and Hookworm Infection on Pregnancy Course and Outcome in Women Living in the Democratic Republic of the Congo.
Campillo J, Chabot E, Awaca-Uvon N, et al. The American journal of tropical medicine and hygiene. 2021.
Read more
   


No Serological Evidence of Trachoma or Yaws Among Residents of Registered Camps and Makeshift Settlements in Cox's Bazar, Bangladesh
Cooley GM, Feldstein LR, Bennett SD, et al. American Society of Tropical Medicine and Hygiene. The American Journal of Tropical Medicine and Hygiene. 2021; 104 (6) : 2031-2037.
Read more
   


Determining the vocational competencies required to deliver community-based rehabilitation and inclusive development services in India
Gale L, Gillis S, Grills N. Informa UK Limited. Disability and Rehabilitation. 2021.
Read more
   


The role of diagnostic technologies to measure progress toward WHO 2030 targets for soil-transmitted helminth control programs
Stuyver LJ, Levecke B, Foster GM. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009422. 
Read more
   


An anthropological study on local community and peripheral health centre staff perceptions and practices regarding sleeping sickness in Vwaza Marsh Wildlife Reserve in Malawi
Munthali A. DNDI. 2021.
Read more
   


The control of soil-transmitted helminthiases in the Philippines: the story continues
Mationg MLS, Tallo VL, Williams GM, et al. Springer Science and Business Media LLC. Infectious Diseases of Poverty. 2021.
Read more
   


Diagnosing point-of-care diagnostics for neglected tropical diseases
Bharadwaj M, Bengtson M, Golverdingen M, et al. Public Library of Science (PLoS). PLOS Neglected Tropical Diseases. 2021; 15 (6) : e0009405. 
Read more
   


Long-term sequelae of congenital gambiense human African trypanosomiasis
Mudji J, Künzli E, Molyneux D, et al. Oxford University Press (OUP). Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021.
Read more
   


Foot Care Practice and Associated Factors among Patients with Lymphoedema in Boreda District, Gamo Zone, SNNPR, Ethiopia, 2020. Implications for Elimination of Podoconiosis and Lymphatic Filariasis
Churko C, Yohanes T, Kassahun AB, et al. Research Square Platform LLC. 2021.
Read more
   


Subcutaneous mycoses in Ethiopia: a retrospective study in a single dermatology center
Abate DA, Ayele MH, Mohammed AB. Oxford University Press (OUP). Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021.
Read more
   


Water sanitation and hygiene in Sub-Saharan Africa: Coverage, risks of diarrheal diseases, and urbanization
Zerbo A, Castro Delgado R, Arcos González P. Elsevier BV. Journal of Biosafety and Biosecurity. 2021; 3 (1) : 41-45. 
Read more
   


Snakebite envenoming in different national contexts: Costa Rica, Sri Lanka, and Nigeria
Gutiérrez JM, Maduwage K, Iliyasu G, et al. Elsevier BV. Toxicon: X. 2021.
Read more
   

 

 

News & Webinars 

 

 

LSE: Cutting aid will increase distrust in Africa's COVID-19 vaccine rollout
The G7 has promised to donate 1 billion Covid vaccine doses by the end of 2021. However, in South Sudan, COVID restrictions, aid cuts and comments by European leaders have shattered trust in public health advice and encouraged vaccine hesitancy. Despite the rhetoric, donating vaccines while cutting aid may prove meaningless.
Read more
  


WHO Technical Advisory Group on schistosomiasis and soil-transmitted helminthiases control and elimination
WHO is seeking experts to serve as members of a new Technical Advisory Group on control and elimination of schistosomiasis and soil-transmitted helminthiases. This call for experts provides information about the advisory group, the expert profiles being sought, the process used to express interest, and the process of selection.
Read more
  


Webinar: Reaching the Criteria to Stop Treatment for Onchocerciasis
One of the most challenging steps for onchocerciasis endemic countries is breaking the cycle of transmission to the point where mass drug administration can be stopped. USAID's Act to End NTDs | East (Act | East) program has learned valuable lessons through supporting countries to reach this critical milestone in their journey to achieve the elimination of onchocerciasis. Please join them for a webinar to share lessons learned from Ethiopia, Nigeria, and Uganda.
Register now
  


10th SPJ Online Seminar: Ms. Thoko Elphick-Pooley (Director at Uniting to Combat Neglected Tropical Diseases (NTDs)) x Dr. Aya Yajima (Technical officer (NTDs) at the World Health Organization)
This seminar is the 10th session of the SPJ Online Seminar Series "Global Health in the Age of Covid-19: Infectious Diseases and Human Security". 
Register now
  


Enabling a Paradigm Shift to a country-led response to deliver the NTD Road Map
With the theme, Enabling a paradigm shift to a country-led response to deliver the NTD Road Map, the 2021 NNN Conference is looking to be the most forward-thinking yet. This free three-day event will feature 18 exciting workshops and two rapid fire sessions highlighting the BEST Framework's role in accelerating progress on NTDs toward 2030. The plenaries will include a high-level panel discussion and exciting NTD Innovation Prizes. 
The 12th Annual Neglected Tropical Disease NGO (NNN) Conference will take place from Tuesday 7th - Thursday 9th September 2021. 
Click here to register
  


2nd LEAP Scientific Conference
The 2nd LEAP Scientific Conference 'Scientific innovation and access for leishmaniasis management' will take place virtually on 2-4 November 2021.
Abstract submission deadline is on 30th June 2021 at 11:30pm East Africa Time (EAT)
  


The tenth EDCTP Forum will be online from 17 – 21 October 2021, because of the COVID-19 travel restrictions.  The Forum's theme this year is: 'Equity in research for health'. This virtual meeting will be streamed from the Joaquim Chissano International Conference Centre in Maputo Mozambique.
Registration is free charge
  


ISNTD Connect - A series of online short meetings to learn, share and stay connected  

Sign up to receive details of upcoming ISNTD Connect meetings or view a recording of the many interesting webinars that were held in the past months. 
   

 

 

GDPR & the InfoNTD newsletter 

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our privacy statement and mailing list. InfoNTD sends out monthly e-mails to its subscribers with an overview of recent publications on NTDs and cross-cutting issues. The purpose of this activity is to keep subscribers up to date. InfoNTD will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else. You can update your preferences or unsubscribe from this list at any time.  

 


LML - S Deepak, B Naafs, S Noto and P Schreuder 

LML blog link: http://leprosymailinglist.blogspot.it/ 

Contact: Dr Pieter Schreuder << editorlml@gmail.com